Combinatorial treatment with EpCAM-ReTARGpp65 and EGFR-ReTARGIE−1, which additionally recruits HLA-C*07:02-restricted anti-CMVIE-1 CD8pos T cells, strongly potentiated selective cancer cell elimination compared to single-agent treatment, likely due to the concurrent cytolytic action of both cognate anti-CMV CD8pos T cell clones. The gene discussed is EPCAM; the disease is cancer.